CompanyKPTINasdaqNewton, MA

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is a commercial-stage pharmaceutical company developing nuclear export inhibitors for cancer.

SEC EDGAR ClinicalTrials.gov

424B3Sep 25Latest SEC filing

Sep 25Latest story

September 2026

Loxo posts Phase 3 pirtobrutinib results; five more Lilly-linked trials update

Sep 25Weekly roundup, 6 itemsabemaciclib brenipatide

August 2026

Karyopharm says myelofibrosis sNDA submission remains on track for August

Aug 13Quarterly updateKaryopharm Therapeutics Inc

July 2026

Karyopharm discloses 2026 cash retention program details for top executives

Jul 17PeopleKaryopharm Therapeutics Inc